- Home
- HUDI vs INAB Comparison
HUDI vs INAB Comparison
Compare HUDI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- INAB
- Stock Information
- Founded
- HUDI 1998
- INAB 2016
- Country
- HUDI China
- INAB United States
- Employees
- HUDI N/A
- INAB N/A
- Industry
- HUDI Steel/Iron Ore
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- HUDI Industrials
- INAB Health Care
- Exchange
- HUDI Nasdaq
- INAB Nasdaq
- Market Cap
- HUDI 28.4M
- INAB 24.0M
- IPO Year
- HUDI 2021
- INAB 2021
- Fundamental
- Price
- HUDI $1.99
- INAB $0.32
- Analyst Decision
- HUDI
- INAB Strong Buy
- Analyst Count
- HUDI 0
- INAB 3
- Target Price
- HUDI N/A
- INAB $7.75
- AVG Volume (30 Days)
- HUDI 15.0K
- INAB 1.0M
- Earning Date
- HUDI 08-06-2024
- INAB 11-12-2024
- Dividend Yield
- HUDI N/A
- INAB N/A
- EPS Growth
- HUDI N/A
- INAB N/A
- EPS
- HUDI 0.18
- INAB N/A
- Revenue
- HUDI $83,462,634.00
- INAB N/A
- Revenue This Year
- HUDI N/A
- INAB N/A
- Revenue Next Year
- HUDI N/A
- INAB N/A
- P/E Ratio
- HUDI $10.86
- INAB N/A
- Revenue Growth
- HUDI 7.65
- INAB N/A
- 52 Week Low
- HUDI $1.88
- INAB $0.22
- 52 Week High
- HUDI $4.25
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- HUDI 48.92
- INAB 55.74
- Support Level
- HUDI $1.99
- INAB $0.29
- Resistance Level
- HUDI $2.09
- INAB $0.41
- Average True Range (ATR)
- HUDI 0.06
- INAB 0.04
- MACD
- HUDI 0.02
- INAB 0.00
- Stochastic Oscillator
- HUDI 57.89
- INAB 49.25
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Products are exported to the United States, Mexico, Thailand, Australia, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.